SC 002 - Stemcentrx

Drug Profile

SC 002 - Stemcentrx

Alternative Names: SC-002

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator Stemcentrx
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neuroendocrine tumours; Small cell lung cancer

Most Recent Events

  • 01 Jul 2015 Phase-I clinical trials in Small cell lung cancer (Second-line therapy or greater) in USA (IV)
  • 01 Jul 2015 Phase-I clinical trials in Neuroendocrine tumours (Second-line therapy or greater) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top